1. Benzimra, J, et al. Hepatic cysts treated with percutaneous ethanol sclerotherapy: time to extend the indications to haemorrhagic cysts and polycystic liver disease. Eur Radiol. 2014; 24(5):1030–1038.
2. Abu-Wasel, B, et al. Pathophysiology, epidemiology, classification and treatment options for polycystic liver diseases. World J Gastroenterol. 2013; 19(35):5775–5786.
3. Fedeles, SV, et al. A genetic interaction network of five genes for human polycystic kidney and liver diseases defines polycystin-1 as the central determinant of cyst formation. Nat Genet. 2011; 43(7):639–647.
4. Gevers, TJ, et al. Somatostatin analogues for treatment of polycystic liver disease. Curr Opin Gastroenterol. 2011; 27(3):294–300.
5. Venkatanarasimha, N, et al. Imaging features of ductal plate malformations in adults. Clin Radiol. 2011; 66(11):1086–1093.
6. Everson, GT, et al. Advances in management of polycystic liver disease. Expert Rev Gastroenterol Hepatol. 2008; 2(4):563–576.
7. Morgan, DE, et al. Polycystic liver disease: multimodality imaging for complications and transplant evaluation. Radiographics. 2006; 26(6):1655–1668. .
8. Brancatelli, G, et al. Fibropolycystic liver disease: CT and MR imaging findings. Radiographics. 2005; 25(3):659–670.
9. Qian, Q, et al. Clinical profile of autosomal dominant polycystic liver disease. Hepatology. 2003; 37(1):164–171.
10. Mortele, KJ, et al. Cystic focal liver lesions in the adult: differential CT and MR imaging features. Radiographics. 2001; 21(4):895–910.